Nusinersen is used in the treatment of spinal muscular atrophy and induces inclusion of SMN2 Exon 7 through steric blocking of an intronic splicing silencer downstream of the exon, leading to increased production of full-length and functional SMN protein from SMN2 [14]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.